Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVO-STEMI trial of evolocumab in STEMI patients undergoing primary PCI
KCT0005323Phase 3Completed
- Sponsor
- Korean Society of International Cardiology, Daewoong, Woochon Cardio-Neuro-Vascular Research Foundation, Terumo Corporation
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of evolocumab in myocardial infarction (MI) (2 arms), sponsored by Korean Society of International Cardiology, Daewoong, Woochon Cardio-Neuro-Vascular Research Foundation, Terumo Corporation. Primary endpoint: Percent myocardial infarct size. Started Dec 2020; status: completed.
02
Drugs
evolocumab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on KCT0005323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005323.